Treatment capacity required for full-scale implementation of lung cancer screening in the United States

Cancer
Erik F BlomHarry J de Koning

Abstract

Full-scale implementation of lung cancer screening in the United States will increase detection of early stages. This study was aimed at assessing the capacity required for treating those cancers. A well-established microsimulation model was extended with treatment data from the National Cancer Database. We assessed how treatment demand would change when implementing lung cancer screening in 2018. Three policies were assessed: 1) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 80 years, with a smoking history of at least 30 pack-years (US Preventive Services Task Force [USPSTF] recommendations); 2) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 77 years, with a smoking history of at least 30 pack-years (Centers for Medicare and Medicaid Services [CMS] recommendations); and 3) annual screening of current smokers and former smokers who quit fewer than 10 years ago, aged 55 to 75 years, with a smoking history of at least 40 pack-years (the most cost-effective policy in Ontario [Ontario]). The base-case screening adherence was a constant 50%. Sensitivity analyses assessed other adherence levels, including a linear buildup to 50%...Continue Reading

References

Oct 16, 1999·The New England Journal of Medicine·P B BachC B Begg
Dec 29, 2004·Annals of Surgery·Philip P GoodneyJohn D Birkmeyer
Jul 29, 2009·Circulation·Atul GroverIrving Kron
Mar 29, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Filippo de MarinisUNKNOWN Italian Association of Thoracic Oncology
Jul 1, 2011·The New England Journal of Medicine·UNKNOWN National Lung Screening Trial Research TeamJoRean D Sicks
May 24, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Erik M von MeyenfeldtMichel W J M Wouters
Feb 19, 2013·The Annals of Thoracic Surgery·Shawn S GrothElizabeth B Habermann
Jan 1, 2014·Annals of Internal Medicine·Virginia A Moyer, UNKNOWN U.S. Preventive Services Task Force
Jan 21, 2014·American Journal of Preventive Medicine·Theodore R HolfordEric J Feuer
Jun 26, 2014·The Annals of Thoracic Surgery·Janet P EdwardsSean C Grondin
Aug 15, 2014·Journal of Medical Screening·Fabrice SmieliauskasYa-Chen Tina Shih
Oct 15, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Kevin Ten HaafHarry J de Koning
Jan 31, 2017·JAMA Internal Medicine·Linda S KinsingerGeorge L Jackson
Dec 10, 2017·The Journal of Thoracic and Cardiovascular Surgery·Susan Moffatt-BruceThomas E Williams
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Nov 18, 2020·Respirology : Official Journal of the Asian Pacific Society of Respirology·Nicole M RankinHenry M Marshall
Jan 29, 2022·The American Journal of Hospice & Palliative Care·Mengting ChenShihong Liu

❮ Previous
Next ❯

Software Mentioned

MISCAN
Blom
Lung
R

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.